Top news of the week: 28.07.2021.
Startups
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Original Article from The New England Journal of Medicine — Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.
The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.
How are startups spending record amounts of funding? On jobs, not offices
If you are a living human who is in some way employable by a biotech or tech company, someone wants to hire you at a healthy salary.
NVCA Member Spotlight: Longitude Capital
In this NVCA Member Spotlight, we spoke to Juliet Tammenoms Bakker and Patrick Enright, Managing Directors at Longitude Capital, to learn more about their firm.
IPO Raises $304M for Caribou, Developer of Gene-Edited Cell Therapies
Caribou Biosciences, the developer of gene-edited cell therapies co-founded by Nobel laureate Jennifer Doudna, PhD, has launched an upsized initial public offering that raised $304 million ...
Toronto A.I. meets Boston biotech: Deep Genomics raises $180 million to automate drug discovery
The startup aims to save drugmakers time and money during research and development, and give them access to key information and patterns through software tools.
Caribou raises $304M in one of gene editing's most lucrative IPOs
The IPO is several times larger than what CRISPR Therapeutics, Intellia and Editas raised several years ago, and ranks well ahead of a more recent offering from gene editing startup Beam.
LHS Expert Insights: ESG Issues for Life Science Innovators
Interviews with our senior practice managers about issues of important to life science innovators Paul Sagan, Vice President of Investor Relations and Corporate Communications, discusses ...